Brief: Cel-Sci’S Multikine Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Versus 48.6%) In The Group Receiving Surgery Plus Radiotherapy

CEL-SCI

28/06/2021 14:37

June 28 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI’S MULTIKINE® IMMUNOTHERAPY PRODUCES SIGNIFICANT
14.1%
5-YEAR SURVIVAL BENEFIT (62.7% VERSUS 48.6%) IN THE GROUP
RECEIVING SURGERY PLUS RADIOTHERAPY IN A LANDMARK HEAD AND NECK
CANCER PHASE 3 STUDY
    * CEL-SCI - DATA INDICATE SIGNIFICANT OVERALL SURVIVAL
BENEFIT FOR
PATIENTS WHO RECEIVED MULTIKINE TREATMENT REGIMEN FOLLOWED BY
SURGERY & RADIOTHERAPY
    * CEL-SCI - PATIENTS TREATED WITH MULTIKINE TREATMENT
REGIMEN
FOLLOWED BY SURGERY AND RADIOTHERAPY DEMONSTRATED STATISTICALLY
SIGNIFICANT OS ADVANTAGE

Source text for Eikon:  ID:nBw4PpRnva 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))